Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Salipro, Boehringer Ingelheim Ink Deal to Boost Multiple Pipeline Programs
Details : The collaboration aims to advance the discovery of new solutions targeting GPCRs, transporters and other integral membrane proteins in therapeutic areas such as cardio-renal-metabolic diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Sumitomo
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Through collaboration, Salipro will utilize its expertise in stabilizing challenging membrane proteins via its Salipro® technology to advance Sumitomo's drug discovery program by characterizing a drug with the desired therapeutic properties against a se...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Sumitomo
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Icosagen
Deal Size : Undisclosed
Deal Type : Collaboration
Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration
Details : The collaboration aims to advance drug discovery programs against several challenging membrane proteins, including G protein-coupled receptors (GPCRs) and solute carrier (SLC) transporters for the discovery and characterization of monoclonal antibodies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Icosagen
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : DyNAbind
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration combines the benefits of Salipro's proprietary platform technology for discovery of small molecule that bind to a membrane protein drug target with DyNAbind’s DNA-Encoded Library technology to accelerate the development of novel drugs...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : DyNAbind
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration brings together Salipro Biotech’s unique expertise in developing stable antigens of GPCRs, ion channels and transporters via its proprietary Salipro® platform with Sanofi’s discovery programs to identify biologics with the desired ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration